Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors by Pello, Ana María et al.
 1 
Original Articles 
Differential profile in inflammatory and mineral metabolism biomarkers in 
patients with ischemic heart disease without classical coronary risk factors 
 
Ana María Pello, MD,a Carmen Cristóbal, MD, PhD,b,c Nieves Tarín, MD, PhD,d Ana Huelmos, 
MD, PhD,e Álvaro Aceña, MD,a Rocío Carda, MD,a María Luisa González-Casaus, MD,f 
Joaquín Alonso, MD, PhD,b,c Óscar Lorenzo, PhD,g,h Luis Blanco-Colio, PhDg, José Luis 
Martín-Ventura, PhDg,h, Juan Antonio Franco Peláez, MD, PhD,a Ignacio Mahíllo-Fernández, 
PhD,i Jerónimo Farré, MD, PhD,a,h Lorenzo López-Bescós, MD, PhD,c Jesús Egido, MD, 
PhD,g,h,j,k José Tuñón, MD, PhD,a,g,h 
 
aDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Madrid, Spain; bDepartment of 
Cardiology, Hospital de Fuenlabrada, Fuenlabrada, Spain; cRey Juan Carlos University, 
Alcorcón, Spain; dDepartment of Cardiology, Hospital Universitario de Móstoles, Spain; 
eDepartment of Cardiology, Hospital Universitario Fundación Alcorcón, Spain; fLaboratory of 
Nephrology and Mineral Metabolism, Hospital Gómez-Ulla, Madrid, Spain; gLaboratory of 
Vascular Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain; hAutónoma University, 
Madrid, Spain; iDepartment of Epidemiology, IIS-Fundación Jiménez Díaz, Madrid, Spain; 
jDepartment of Nephrology, IIS-Fundación Jiménez Díaz; kCIBERDEM, Madrid, Spain. 
 
Corresponding author: José Tuñón, MD, Ph.D., Department of Cardiology, IIS-Fundación 
Jiménez Díaz, Avenida Reyes Católicos 2, 28040 Madrid (Spain), Phone (+34) 91550480 Ext 
3701, email jtunon@secardiologia.es, Fax (+34) 915504904 
 
Keywords: coronary artery disease, atherosclerosis, cardiovascular risk factors, biomarkers, 
fibroblast growth factor-23, monocyte chemoattractant protein-1. 
Word Count: 3865 
 2 
ABSTRACT 
BACKGROUND 
Patients with coronary heart disease (CHD) without classical cardiovascular risk factors 
(CRF) are uncommon, and their profile has not been thoroughly studied. In CHD patients, we 
have assessed the differences in several biomarkers between those with and without CRF. 
METHODS  
We studied 704 patients with CHD, analyzing plasma levels of biomarkers related to 
inflammation, thrombosis, renal damage, and heart failure: hs-CRP (high-sensitivity C-reactive 
protein), MCP-1 (monocyte chemoattractant protein-1), galectin-3, NT-pro-BNP (N-terminal 
fragment of brain natriuretic peptide), calcidiol (vitamin D metabolite), fibroblast growth factor-
23 (FGF-23), parathormone, and phosphate. 
RESULTS 
Twenty patients (2.8%) exhibited no CRFs. Clinical variables were well balanced in 
both groups, with the logical exceptions of no use of antidiabetic drugs, lower triglyceride and 
glucose, and higher high-density lipoprotein cholesterol in no-CRF patients. 
No-CRF patients showed lower hs-CRP (2.574±3.120 vs 4.554±9.786 mg/L; P=0.018), 
MCP-1 (114.75±36.29 vs 143.56±65.37 pg/ml; P=0.003) and FGF-23 (79.28±40.22 vs 
105.17±156.61 RU/ml; P=0.024) and higher calcidiol (23.66±9.12 vs 19.49±8.18 ng/ml; 
P=0.025) levels. At follow-up, 10.0% vs 11.0% patients experienced acute ischemic event, heart 
failure, or death in the non-CRF and CRF groups, respectively (P=0.815, log-rank test). The 
limited number of non-CRF patients may have influenced this finding. A Cox regression 
analysis in the whole population showed that high calcidiol, and low MCP-1 and FGF-23 
plasma levels are associated to a better prognosis. 
CONCLUSIONS 
CHD patients without CRFs show a favorable biomarker profile in terms of inflammation and 
mineral metabolism. Further studies are needed to investigate whether this difference translates 
into a better prognosis. 
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INTRODUCTION 
The importance of cardiovascular risk factors (CRF) in the development of coronary 
heart disease (CHD) is well established, and it is widely recognized that they must be controlled 
in order to halt the progression of the disorder.[1] However, some patients with CHD do not 
present classical CRFs. Although these patients are managed similarly to patients that have 
CRFs, they sometimes show differences as compared to those with CRFs. In spite of this, less 
attention has been paid to this subgroup. 
In recent years there has been growing interest in the role of prognostic biomarkers in 
atherothrombosis. It has been shown that increased levels of high-sensitivity C reactive protein 
(hs-CRP), monocyte chemoattractant protein-1 (MCP-1), galectin-3, and N-terminal probrain 
natriuretic peptide (NT-proBNP) are related to an adverse prognosis.[2-8] More recently, 
plasma levels of the components of mineral metabolism, such as vitamin D, fibroblast growth 
factor-23 (FGF-23), parathormone, and phosphate have also been related to cardiovascular 
disorders.[9-12] 
We have investigated whether CHD patients who do not have CRFs present a more 
favorable profile of prognostic biomarkers related to atherothrombosis. We divided a population 
of 704 patients with CHD into those with and without CRFs. These patients were examined 
according to a panel of biomarkers related to inflammation, thrombosis, renal damage, and heart 
failure: hs-CRP, MCP-1, galectin-3, and NT-pro-BNP.[2-8] In addition, we determined the 
levels of the components of mineral metabolism in the patients’ plasma: calcidiol (a metabolite 
of vitamin D), FGF-23, parathormone, and phosphate.  
 
METHODS 
Patients 
The research protocol was approved by the ethics committees of the participating 
hospitals and all patients signed informed consent documents. The BACS & BAMI (Biomarkers 
in Acute Coronary Syndrome & Biomarkers in Acute Myocardial Infarction) studies included 
patients admitted to four hospitals in Madrid who had either non-ST elevation acute coronary 
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syndrome or ST-elevation acute myocardial infarction, as described previously.[5] Exclusion 
criteria were: age over 85 years, coexistence of other significant cardiac disorders except left 
ventricular hypertrophy secondary to hypertension, coexistence of any illness or toxic habits 
that could limit patient survival, impossibility to perform revascularization when indicated, and 
subjects in whom follow-up was not possible. In order to limit the variability of the findings due 
to an excessive heterogeneity in the intervals between the acute event and blood extraction, the 
investigators agreed to exclude patients who were not clinically stable at day six of the index 
event. 
 In addition to plasma withdrawal at discharge, a second plasma sample was extracted 
on an outpatient basis between six and twelve months later, on an outpatient basis. This paper 
reports data from the clinical and analytic findings obtained during this second plasma 
extraction. 
 Between July 2006 and April 2010, 1,898 patients who had experienced an acute 
coronary event were discharged from the participating hospitals. Of these, 838 were included in 
the study. The remaining patients were not included due one of the following reasons: age over 
85 years (17.3%), disorders or toxic habits limiting survival (29.0%), impossibility to perform 
cardiac revascularization (14.5%), coexistence of other significant cardiopathy (6.8%), 
impossibility to perform follow-up (12.0%), clinical instability beyond the sixth day at the index 
event (9.1%), refusal to participate in the study (2.0%), and impossibility of the investigators to 
include them (9.3%). Of the patients included, 7 died before the second plasma extraction and 
709 had available and adequate plasma samples at the time. This visit took place between 
January 2007 and February 2011. The patients were included in a follow-up study, with the last 
visits taking place in May 2012. Five patients were lost to follow-up, leaving a total of 704 
patients for analysis.  
  
Study Design 
 The cross-sectional sudy was carried out during the visit performed six to twelve 
months after the acute coronary event. Blood was withdrawn from the patients for plasma 
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storage and a complete set of clinical variables was recorded. Twelve-hour fasting venous blood 
samples were collected in ethylenediaminetetraacetate tube (EDTA). Patients were considered 
to present hypertension if they had a history of systolic and/or diastolic pressure equal to or 
higher than 140 and 90 mm Hg, respectively [13] or if they were taking blood-pressure-
lowering drugs for this disorder. Patients with current or past tobacco use were considered 
smokers. Patients receiving lipid-lowering therapy for this diagnosis and those with fasting lipid 
levels (LDL cholesterol>160 mg/dl and/or triglyceride levels>200 mg/dl) were considered to be 
diagnosed with dyslipidemia.[14] Patients were considered  to present a family history of 
atherosclerosis when a first-degree relative younger than 60 years had history of CHD, 
peripheral vascular disease or cerebrovascular diease.[15]Finally, patients were considered to be 
diabetics if they were receiving therapy for the disease or if they had fasting glucose levels > 
126 mg/dl.[16] 
A prospective observational study was also initiated during this visit. Under the study, 
patients were seen every year at their hospital. At the end of follow-up (maximum 4.6 years), 
the patients’ medical records were reviewed and patient status was confirmed by telephone 
contact made by a cardiologist. The outcome variable was the combination of acute thrombotic 
events (any acute coronary syndrome, stroke, and transient ischemic attack) plus all-cause 
mortality and heart failure, defined as described previously.[5]  
 
Biomarker and analytical studies 
Venous blood samples were centrifuged at 2,500 g for 10 minutes. Plasma was stored at 
-80°C in the biobank of IIS-Fundación Jiménez Díaz. Plasma determinations of calcidiol, FGF-
23, and intact parathormone were performed at the laboratory of Nephrology and Mineral 
Metabolism at the Gómez-Ulla hospital. The remaining determinations were carried out at the 
Vascular Pathology and Biochemistry Laboratories at Fundación Jiménez Díaz. The 
investigators who performed the laboratory studies were unaware of clinical data. Plasma 
calcidiol levels were quantified by chemiluminescent immunoassay (CLIA) using the 
LIAISON® XL analyzer (LIAISON 25OH Vitamin D total Assay DiaSorin, Saluggia, Italy), 
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FGF-23 was measured by an enzyme-linked immunosorbent assay that recognizes epitopes 
within the carboxyl-terminal portion of FGF-23 (Human FGF-23, C-Term, Immutopics Inc, San 
Clemente, CA), intact parathormone was analyzed by a second-generation automated 
chemiluminescent method (Elecsys 2010 platform, Roche Diagnostics, Mannheim, Germany), 
and phosphate was determined through an enzymatic method (Integra 400 analyzer, Roche 
Diagnostics, Mannheim, Germany). Plasma concentrations of MCP-1 and galectin-3 were 
determined in duplicate using commercially available enzyme-linked immunosorbent assay kits 
(BMS279/2 Bender MedSystems, and DCP00, R&D Systems, respectively) following the 
manufacters’ instructions. Intra- and inter-assay coefficients of variation were 4.6% and 5.9% 
for MCP-1 and 6.2% and 8.3% for galectin-3, respectively. Hs-CRP was assessed by latex-
enhanced immunoturbidimetry (ADVIA 2400 Chemistry System, Siemens, Germany), and NT-
pro-BNP was analyzed by immunoassay (VITROS, Orthoclinical Diagnostics, U.S.A.). Lipids, 
glucose, and creatinine determinations were performed by standard methods (ADVIA 2400 
Chemistry System, Siemens, Germany). 
 
Statistical analysis 
Quantitative data that followed a normal distribution are presented as mean±standard 
deviation and compared using the Student “t” test. When normal distribution could not be 
assumed, median (interquartile range) and Mann-Whitney test were used. Qualitative variables 
are displayed as percentages and were compared by X2 or Fisher exact test where appropriate. 
Log-rank test were used to compare time to outcome in patients without CRFs against those 
who had CRFs. Cox regression analysis was performed with forward, stepwise selection, to 
assess the predictive value of the biomarkers studied for the development of the outcome, 
controlling for all the variables shown in Table 1. Analyses were performed with SPSS 19.0 
(SPSS Inc., New York) and R 3.0.1. (http://www.r.project.org/). 
  
 
RESULTS 
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Of the 704 patients included, only 20 (2.8%) did not present any classical CRFs. Forty 
percent of these patients were women (Table 1). Age was similar in the non-CRF and the CRF 
groups, and there were no significant differences in the clinical variables between both groups, 
with the exception of the intake of antidiabetic drugs, which was more frequent in the CRF 
group (18.3 vs. 0%; P=0.034). Glucose (93.7 vs. 109.6 mg/dl; P=0.001) and triglycerides 
(95.5±40.3 vs. 132.1±83.6 mg/dl; P<0.001) plasma levels were lower in the non-CRF group 
than in patients with CRFs. On the other hand, HDL-cholesterol levels were higher in the 
absence of CRFs (50.3±11.7 vs. 43.6±10.8 mg/dl; P=0.007). 
 The biomarker study showed lower hs-CRP (2.574±3.120 vs 4.554±9.786 mg/L; 
P=0.018) and MCP-1 (114.75±36.29 vs 143.56±65.37 pg/ml; P=0.003) plasma levels in the 
non-CRF as compared to the CRF group. The analysis of the components of mineral 
metabolism showed lower FGF-23 levels in patients without CRF as compared to those with 
CRFs (79.28±40.22 vs 105.17±156.61 RU/ml; P=0.024). On the other hand, calcidiol plasma 
levels were higher in the non-CRF than in the CRF group (23.66±9.12 vs. 19.49±8.18 ng/ml 
respectively; P=0.025). No differences were found in the remaining biomarkers assessed (Table 
1). Using linear regression analysis, we estimated that glycemia, HDL-cholesterol, and 
triglyceride plasma levels only explained 3.0% (R2=0.030), 0.1% (R2=0.001), 0.3% (R2=0.003), 
and 6% (R2=0.062) of the variations in hs-CRP, MCP-1, FGF-23, and calcidiol levels, 
respectively.   
As the low number of patients without CRFs could have masked significant differences 
in age and gender, we carried out a new analysis comparing the non-CRF group to a control 
group of 40 age- and sex-matched patients with CRFs. The results of this analysis were similar 
to those of the overall assessment (Table 1). There were lower glucose (93.7±18.3 vs. 
113.6±32.1 mg/dl; P=0.004) and MCP-1 (114.75±36.29 vs. 158.32±72.67 pg/ml; P=0.003] 
plasma levels in the non-CRF group. In addition, calcidiol levels were also higher in the non-
CRF than in the CRF group (23.66±9.12 vs. 18.67±7.06 ng/ml; P=0.023). There was a trend 
towards a reduction in FGF-23 and hs-CRP levels in patients without CRF; this difference failed 
to reach statistical significance, probably due to the lower sample size of both groups in this 
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confirmation study. Similarly, differences in the use of oral antidiabetic drugs, and in 
triglyceride and HDL plasma levels did not reach statistical significance. 
After 2.12 (1.37-2.98) years of follow-up, 2 patients (10%) in the non-CRF group and 
75 patients (10.96%) in the CRF group reached the prespecified outcome. Of the 2 patients in 
the non-CRF group, 1 suffered a stroke and the other developed a non-ST segment elevation 
myocardial infarction. In the CRF group, there were 38 non-ST segment elevation acute 
coronary syndromes, 4 cases of ST-segment elevation myocardial infarction, 7 strokes, 10 
transitory ischemic attacks, 16 hospital admissions due to heart failure and 22 deaths. Twelve 
patients developed two events and 5 patients experienced three events. There were no 
significant differences between the two groups (P=0.816, log-rank test). 
 All variables shown in Table 1 were entered into a multivariate Cox model to 
investigate the predictive value of the biomarkers studied in the whole population. In this 
analysis, low calcidiol and high FGF-23 and MCP-1 plasma levels were independent predictors 
of outcome, along with age, insulin, and angiotensin converting enzyme inhibitors or 
angiotensin receptor blockers treatment (Table 2).  
 
 
DISCUSSION 
Most patients with established CHD have some classical CRF. Nonetheless, a small 
proportion of them are free of CRFs. However, little attention has been paid to these patients.  
Only 20 out of the 704 patients (2.8%) included in our study had no CRFs. This value is 
lower than those reported previously.(17) The published data vary depending on the population 
analyzed, cutoff values used in the definition of CRFs, and age. Age is considered an 
independent CRF,[1] and the proportion of patients without classical CRFs increases with age 
[17] as we observed in our study. Male gender is also correlated with higher cardiovascular 
risk,[18] and in our population there was a higher proportion of men than women. However, we 
did not find significant differences in gender distribution between patients with and without 
CRFs, although this could be due to the small number of patients without CRFs.  
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 Both groups showed a similar distribution of clinical variables; the only exception to 
this was that the CRF group contained more patients under oral antidiabetic therapy. This 
difference is logical as, by definition, diabetic patients could only belong to the CRF group. 
Although similar data could be expected to be present with regard to the use of lipid and blood 
pressure lowering drugs, this was not the case. The percentage of patients receiving treatment 
with statins was similar in both groups, because aggressive lipid lowering is indicated in all 
patients after an acute coronary event.[19] With regard to antihypertensive patients, modulators 
of the renin-angiotensin system are indicated in subjects with clinically evident atherosclerosis, 
and even more when left ventricular dysfunction is present.[19] Similarly, beta-blockers are 
beneficial in patients with a history of myocardial infarction.[19] Other blood pressure lowering 
drugs such as diuretics may be adviced in more patients in addition to those with hypertension, 
such as patients who have experienced heart failure. Finally, patients without CRFs had lower 
glycemia, higher HDL-cholesterol, and lower triglyceride plasma levels than those with CRFs, 
according to the criteria used to allocate them into one of the two groups. 
 Inflammation is an important process both in atherogenesis and plaque 
complication.[20] In this regard, hs-CRP plasma levels have been associated with an increased 
incidence of cardiovascular events.[2,3] In our study, patients without CRFs had lower hs-CRP 
levels than those with classical CRFs. Accordingly, MCP-1 plasma levels were also lower in 
patients without CRFs. MCP-1 is the most important chemokine involved in the 
atherothrombotic process, and it is vital to the recruitment of macrophages into the vessel 
wall.[21] It is expressed more strongly in atherosclerotic lesions than in the healthy vessel.[22] 
Drugs with antiatherosclerotic effects, such as statins, decrease MCP-1 expression in the 
vascular wall.[23] Furthermore, MCP-1 also has procoagulant properties.[24] According to this 
evidence, increased MCP-1 plasma levels have been found to predict the development of 
adverse cardiovascular events in patients with acute coronary syndromes and stable CHD.[4,5] 
Although traditionally related to renal disease, abnormalities in mineral metabolism 
have been associated with cardiovascular disease more recently. When there is a decrease in 
renal glomerular filtration, phosphate elimination is reduced. In order to mantain phospate 
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homeostasis, there is an increase in FGF-23 and parathormone plasma levels. Enhanced plasma 
levels of phosphate, FGF-23, and parathormone have been related to an increase in 
cardiovascular events through different mechanisms, including endothelial dysfunction, arterial 
stiffness, and left ventricular hypertrophy.[9,10,12,25] In addition, FGF-23 reduces vitamin D 
plasma levels.[10] This enhances cardiovascular risk even more, as low vitamin D levels are 
associated with endothelial dysfunction, inflammation, activation of the renin-angiotensin 
system, vascular smooth muscle cell proliferation, and vascular calcification, resulting in 
increased risk of hypertension, CHD and stroke.[11,26-29] In our population, subjects without 
CRFs not only exhibited lower FGF-23 plasma levels, but also revealed increased calcidiol 
levels. This is especially important, since the combination of vitamin D deficit along with 
increased FGF-23 plasma levels seems to confer a higher cardiovascular risk.[30] 
The diminution in hs-CRP, MCP-1, and FGF-23 plasma levels, along with the increase 
in calcidiol levels seems to correlate with a more favorable prognosis in patients without CRFs. 
Although this improved prognosis was not confirmed in our population, this could be due to the 
low number of patients that had no CRFs. Given the very low percentage of CHD patients 
without CRFs, confirmation of a better prognosis would require a very large sample size. 
However, we show than in our whole population low calcidiol and high MCP-1 and 
FGF-23 plasma levels were independent predictors of the outcome, suggesting that the 
biomarker profile on non-CRF patients may be related with a more favorable prognosis. 
This work has some limitations. Excluding patients with clinical instability in the first 
days after the index event could have introduced a certain bias, because these patients would 
probably have had a worse prognosis, and could have also a different distribution of CRFs. The 
low number of patients without CRF in our population could have limited the statistical power 
in the prognosis assessment. This suggests that very large sample sizes of patients with CHD 
must be examined in order to reach more sound conclusions with regard to potential differences 
in the prognosis of both groups. Finally, it must be emphasized that we have published 
previously Cox regression analyses in this population to explore separately the predictive power 
of MCP-1 [5] and that of calcidiol and FGF-23 plasma levels [30]. In the present paper, we have 
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reanalyzed these biomarkers together to support the hypothesis that the biomarker profile of 
non-CRF patients may be associated with a more favorable prognosis.  
 In conclusion, patients with CHD who do not present CRFs display lower plasma levels 
of inflammatory biomarkers and a better profile in the mineral metabolism than those with 
CRFs. These findings could be related to a better prognosis, although we could not confirm this 
difference given the low number of subjects without CRFs found in our population. Further 
studies in large numbers of CHD patients are needed in order to confirm this hypothesis.  
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